Product
Supplier
Encyclopedia
Inquiry
Home > Active Pharmaceutical Ingredients > Antineoplastic Agents (Find 294 items)

Antineoplastic Agents

Antineoplastic agents combat tumors through distinct mechanisms. Alkylating antineoplastic agents form DNA crosslinks, blocking replication. Antimetabolite antineoplastic agents mimic metabolites to disrupt DNA/RNA synthesis. Both classes target rapidly dividing cells but differ in molecular interactions. Read more about Antineoplastic Agents including data on CAS Numbers, properties, materials, and products from the suppliers listed on ECHEMI.

Tandutinib

(387867-13-2)
An oral, small-molecule inhibitor of FLT3 for the treatment of AML (acute myelogenous leukemia)clinical trials in patients with AML and myelodysplastic syndrome, but displayed promising antileukemic activity (90% complete remissions) in a phase I/II trial in patients with newly diagnosed AML when administered in combination with cytarabine and daunorubicin.

Product List

Request for quotation , get quotes from more suppliers.

Tanespimycin

(75747-14-7)
Geldanamycin is a potent inhibitor of Hsp90 that exhibits severe hepatotoxicity when used in vivo. 17-AAG is an analog of geldanamycin which has potent in vivo activity and reduced toxicity. Like other Hsp90 inhibitors, 17-AAG has diverse anti-tumor actions and has potential in treating certain types of cancer. 17-AAG inhibits the growth of prostate cancer cell lines (IC50 = 25-45 nM). 17-AAG promotes the degradation of HER2 and induces growth arrest and apoptosis in breast cancer cells overexpr

Product List

Request for quotation , get quotes from more suppliers.

Valrubicin

(56124-62-0)
Chemotherapy drug used to treat cancer of the bladder.

Product List

Request for quotation , get quotes from more suppliers.

Telatinib

(332012-40-5)
Telatinib small-molecule inhibitor of vascular endothelial growth factor receptors 2 and 3 (VEGFR-2/-3) and platelet-derived growth factor receptor β tyrosine kinases. Telatinib is used therapeutically in patients with advanced solid tumors.

Product List

Request for quotation , get quotes from more suppliers.

(SP-4-2)-[rel-(1R,2R)-1,2-Cyclohexanediamine-κN1,κN2][ethanedioato(2-)-κO1,κO2]platinum

(63121-00-6)
In 1930, the oxidised compound Oxophenarsine, containing an As=O unit, was identified as the active ingredient and was later marketed under the trade name Mapharsen. Mapharsen was used until the 1940s when it was replaced by Penicillin. Mapharsen was actually synthesised in Ehrlich’s laboratory as compound number 5, but it was believed to be too toxic for any clinical application .
Generally, the use of arsenic-based drugs has ceased, especially as a result of the development of Penicillin.

Product List

Request for quotation , get quotes from more suppliers.

Product List

Request for quotation , get quotes from more suppliers.

Canertinib dihydrochloride

(289499-45-2)
The HER family of receptor tyrosine kinases, EGFR, HER2, HER3, and HER4, mediate proliferation, migration, adhesion, differentiation, and survival in many different cell types and have been implicated in the development and progression of a variety of human tumors. Canertinib is an irreversible quinazoline-based HER family tyrosine kinase inhibitor with IC50 values of 0.8, 19, and 7 nM for blocking in vitro activity of EGFR, HER2, and HER4, respectively. As a broadly applicable anti-cancer agent

Product List

Request for quotation , get quotes from more suppliers.

Pentostatin

(53910-25-1)
An adenosine deaminase inhibitor used as an anti-cancer therapeutic drug.Shown to be effective in the treatment of hairy cell leukemia as well as having use in the treatment of other types of cancer such as chronic lymphocytic leukemia.

Product List

Request for quotation , get quotes from more suppliers.

Antineoplastic agents are a class of drugs used to treat tumor diseases. In short, there are chemotherapy drugs and biological agents. At present, there are more than 80 kinds of antineoplastic agents common in the world, which can be roughly divided into the following 6 categories: cytotoxic drugs, hormone drugs, biological response modifiers, monoclonal antibody drugs, other drugs, auxiliary drugs and so on. The "ECHEMI Antineoplastic Agents" list mainly supplies APIs for such drugs.

More Information

Antineoplastic agents are a large group of compounds having different structures but with one common antineoplastic property, namely, to inhibit the proliferation of malignant cells. Through other mechanisms, these agents disrupt DNA replication, inhibiting the cell's metabolism, or inhibiting the essential enzymatic process of the cell. For example, alkylating agents, including bendamustine and dacarbazine, introduce alkyl groups to DNA which causes breakage of the strand and death of the alkylated cell.

Fludarabine phosphate and azathioprine are antimetabolites that mimic the natural substrates and thereby block the synthesis of nucleic acid and inhibit the growth of tumours. These agents have proved efficacious in a variety of malignancies and thus are key components to chemotherapy regimens.

Applications of antineoplastic agents include:

● Treatment of hematologic cancers such as leukemia and lymphoma.

● It is used in the management of solid tumours such as breast, lung and colorectal cancers.

● Conditioning before hematopoietic stem cell transplantation.

● Preventive maintenance therapy for cancer recurrence.

● It’s in combination with other therapeutic modalities, such as radiation and immunotherapy, for the sake of enhancing treatment efficacy.

Frequently Asked Questions

What are Antineoplastic Agents?

Antineoplastic agents, also known as anticancer drugs or chemotherapeutic agents, are pharmaceutical compounds used to treat cancer by inhibiting or preventing the growth and spread of malignant cells. These agents work through various mechanisms, including DNA damage, cell cycle disruption, and inhibition of tumor angiogenesis. They are essential components in oncology treatment regimens worldwide.

How do Antineoplastic Agents work in cancer treatment?

Antineoplastic agents target rapidly dividing cancer cells through several mechanisms:1. Alkylating agents damage DNA to prevent cell replication.2. Antimetabolites interfere with DNA and RNA synthesis.3. Antitumor antibiotics bind to DNA and block replication.4. Mitotic inhibitors disrupt cell division.5. Targeted therapies and immunotherapies specifically attack cancer-related proteins or enhance immune response.The choice of agent depends on cancer type, stage, and patient-specific factors.

What are the common side effects of Antineoplastic Agents?

Due to their action on rapidly dividing cells, antineoplastic agents often cause side effects such as nausea, vomiting, hair loss, fatigue, bone marrow suppression (leading to anemia or increased infection risk), and mucositis. Some agents may also cause long-term effects like cardiotoxicity or infertility. Management strategies include supportive care, dose adjustments, and newer formulations designed to minimize toxicity while maintaining efficacy.

How are high-quality Antineoplastic Agents manufactured and regulated?

High-quality antineoplastic agents are manufactured under strict Good Manufacturing Practice (GMP) guidelines enforced by regulatory bodies like the FDA and EMA. Production involves rigorous quality control at every stage—from raw material sourcing and synthesis to final formulation and packaging. Manufacturers must validate processes, conduct stability testing, and ensure batch-to-batch consistency to guarantee safety, potency, and purity for clinical use.

What should buyers consider when sourcing Antineoplastic Agents from suppliers?

When sourcing antineoplastic agents, buyers should evaluate:1. Regulatory compliance (e.g., GMP, FDA/EMA approvals).2. Documentation including Certificates of Analysis (CoA) and Drug Master Files (DMF).3. Supplier reliability, production capacity, and supply chain transparency.4. Quality assurance systems and history of regulatory inspections.5. Technical support and ability to meet specific purity or formulation requirements.Choosing a reputable supplier ensures therapeutic efficacy and patient safety.

Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.